Home > Cardiology > ESC 2021 > Rivaroxaban improves clinical outcomes in discharged COVID-19 patients

Rivaroxaban improves clinical outcomes in discharged COVID-19 patients

Presented By
Prof. Eduardo Ramacciotti, Santa Casa School of Medicine, Brazil
Conference
ESC 2021
Trial
MICHELLE
The multicentre MICHELLE trial found that thromboprophylaxis with rivaroxaban over 5 weeks after discharge was beneficial for COVID-19 patients. Individuals with moderate to high-risk scores for venous thromboembolism (VTE) had a 67% risk reduction in a composite of various clinical outcomes. The MICHELLE trial (NCT04662684) was designed to explore a possible advantage of prolonged antithrombotic prophylaxis with rivaroxaban for COVID-19 patients after discharge from hospital [1]. The randomised controlled, open-label study, analysed 318 patients that were allocated to treatment with 10 mg of rivaroxaban daily or placebo over 35 days. All adult COVID-19 patients previously received a standard dose thromboprophylaxis during a hospital stay ≥3 days and presented a risk score of ≥4 or a risk score of 2/3 with an initial D dimer >500 ng/mL in the m...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on